Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

1454846-35-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1454846-35-5 Usage


PF-06463922, also known as Lorlatinib, is a novel drug under development for the treatment of a subgroup of advanced non-small cell lung cancer (NSCLC) patients who are ALK or ROS1 positive and have already undergone gene treatment with drugs that specifically target this type of cancer. Lorlatinib is an ATP-competitive, selective inhibitor of anaplastic lymphoma kinase (ALK) and c-Ros oncogene 1 (ROS1), with potent activity against a broad spectrum of ALK resistant mutations. It is designed to inhibit tumor mutations that drive resistance to other ALK inhibitors and to penetrate the blood-brain barrier.


Used in Oncology:
PF-06463922 is used as an anticancer agent for the treatment of advanced non-small cell lung cancer (NSCLC) in patients who are ALK or ROS1 positive and have developed resistance to other ALK inhibitors. It acts by inhibiting the ALK and ROS1 receptor tyrosine kinases, blocking the downstream signaling, and inducing apoptosis, which results in the inhibition of tumor cell proliferation.
Used in Drug Resistance:
PF-06463922 is used as a potent and selective ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations, overcoming the limitations of current therapies and improving treatment outcomes for patients with advanced NSCLC.
Used in Brain Tumor Treatment:
Lorlatinib is used for the treatment of brain tumors in patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), as it demonstrates efficient blood-brain barrier penetration and produces brain tumor regression in mice harboring EML4-ALK tumors, increasing overall survival.
Used in Clinical Trials:
Lorlatinib (PF-06463922) is currently being evaluated in phase II clinical trials as an oral dose at 100 mg daily for the treatment of the specified subgroup of ALK or ROS1 positive NSCLC patients. If marketed, it will become an additional targeted treatment option for this patient population.

Mechanism of Action

Lorlatinib is a kinase inhibitor with in vitro activity against ALK and number of other tyrosine kinase receptor related targets including ROS1, TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, and ACK Label. Lorlatinib demonstrated in vitro activity against multiple mutant forms of the ALK enzyme, including some mutations detected in tumors at the time of disease progression on crizotinib and other ALK inhibitors Label. Moreover, lorlatinib possesses the capability to cross the blood-brain barrier, allowing it to reach and treat progressive or worsening brain metastases as well. The overall antitumor activity of lorlatinib in in-vivo models appears to be dose-dependent and correlated with the inhibition of ALK phosphorylation Label. Although many ALK-positive metastatic NSCLC patients respond to initial tyrosine kinase therapies, such patients also often experience tumor progression. Various clinical trials performed with lorlatinib, however, have demonstrated its utility to effect tumor regression in ALK-positive metastatic NSCLC patients who experience tumor progression despite current use or having already used various first and second-generation tyrosine kinase inhibitors like crizotinib, alectinib, or ceritinib.

Side effects

A third-generation ALK- and ROS1-inhibitor, lorlatinib, has demonstrated activity following progression on one or more ALK inhibitors.Lorlatinib is approved for ALK-positive NSCLC. Similar to other agents in this category, lorlatinib is associated with hepatotoxicity and interstitial lung disease/pneumonitis. CNS toxicities, hyperlipidemia, and atrioventricular block have also been reported.

Biological Activity

pf-06463922 is a potent and selective alk/ros1 inhibitor with ic50 values ranging from 0.19-0.53 nm for the kinase activity of ros1 fusion enzymes [1].the receptor tyrosine kinase c-ros oncogene1 (ros1) is a receptor with a kinase domain that is related to the anaplastic lymphoma kinase/lymphocyte-specific protein tyrosine kinase (alk/ltk) and insulin receptor (insr) rtk families [1].via cellular ros1 autophosphorylation in the recombinant enzyme assay, pf-06463922 showed a 30-fold improved potency against ros1, compared with crizotinib, ceritinib, alectinib and foretinib (xl-880). engineered nih 3t3 cells were expressing oncogenic human ros1 fusions. in these cells, pf-06463922 was more potent than foretinib and crizotinib by >10 folds, more potent than alectinib and ceritinib by >100 folds against cellular ros1 autophosphorylation [1].oncogenic gene fusions involving the 3' region of ros1 kinase had been found in various human cancers [2]. mice bearing cd74-ros1, cd74-ros1g2032r and fig-ros1(s) s.c. tumors (250 mm3) were used. treatments with pf-06463992 at various doses were applied consecutively for 7 or 9 d. at dosages of 0.2 to 1 mg/kg/d, pf-06463922 significantly inhibited the growth of both established figros1(s) and cd74-ros1 tumors compared with vehicle control. at 2-6 mg/kg/d, pf-06463922 significantly made tumor volumes regress (58–85%, p < 0.0001). in animals bearing nih 3t3-cd74-ros1g2032r tumors, treatment with pf-06463922 at 1.0, 3.0, and 10 mg/kg/d significantly inhibited tumor growth by 28%, 44% and 90%, respectively. at 30 mg/kg/d, pf-06463922 made tumor regress by 12%, compared with vehicle [1].

Enzyme inhibitor

This potent, dual ALK/ROS1 inhibitor (FW = 406.41 g/mol; CAS 1454846- 35-5), also named (10R)-7-amino-12-fluoro-10,15,16,17-tetrahydro- 2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3- h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, targets the protooncogene tyrosine-protein kinase ROS1 (Ki < 0.02 nM) as well as wild-type anaplastic lymphoma kinase ALKWT (Ki < 0.07 nM) and its Leu-to-Met mutant ALKL1196M (Ki of = 0.7 nM). PF-06463922 significantly inhibits cell proliferation and induces cell apoptosis in the HCC78 human NSCLC cells harboring SLC34A2-ROS1 fusions and the BaF3-CD74-ROS1 cells expressing human CD74-ROS1


[1]. zou hy, li q, engstrom ld, et al. pf-06463922 is a potent and selective next-generation ros1/alk inhibitor capable of blocking crizotinib-resistant ros1 mutations. proceedings of the national academy of sciences, 2015, 112(11): 3493-3498.[2]. davies kd, le at, theodoro mf, et al. identifying and targeting ros1 gene fusions in non–small cell lung cancer. clinical cancer research, 2012, 18(17): 4570-4579.

Check Digit Verification of cas no

The CAS Registry Mumber 1454846-35-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,5,4,8,4 and 6 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1454846-35:
185 % 10 = 5
So 1454846-35-5 is a valid CAS Registry Number.

1454846-35-5 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (PZ0271)  PF-06463922 acetate  ≥98% (HPLC)

  • 1454846-35-5

  • PZ0271-5MG

  • 983.97CNY

  • Detail

1454846-35-5Downstream Products

1454846-35-5Relevant articles and documents

Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners

Elleraas, Jeff,Ewanicki, Jason,Johnson, Ted W.,Sach, Neal W.,Collins, Michael R.,Richardson, Paul F.

, p. 3590 - 3595 (2016)

Lorlatinib (PF-06463922) is an ALK/ROS1 inhibitor and is in clinical trials for the treatment of ALK positive or ROS1 positive NSCLC (i.e. specific subsets of NSCLC). One of the laboratory objectives for this molecule indicated that it would be desirable

Preparation method of anti-tumor drug Lorlatinib


, (2021/08/21)

The invention relates to a preparation method of an anti-tumor drug Lorlatinib, which comprises the steps of (1) coupling tert-butyl (5-bromo-3-((trimethylsilane) oxy) pyridine-2-yl) carbamate and 1, 3-dimethyl-1H-pyrazole-5-nitrile to obtain a first intermediate; (2) brominating the first intermediate with NBS to obtain a second intermediate; (3) enabling the second intermediate and (R)-1-(5-fluoro-2-N-methylformamide phenyl)-ethanol to be subjected to a one-pot method under the alkaline condition to obtain and a third intermediate; and (4) removing a protecting group from the third intermediate under an acidic condition to obtain the final product Lorlatinib. The method has the advantages of simple and easily available raw materials, short steps, high total yield, relatively convenient operation, low cost, suitability for industrial production and the like.

Application of TBTU in preparation of anti-cancer drug


Paragraph 0028-0048, (2021/03/11)

The invention provides application of TBTU in preparation of an anticancer drug Lorlatinib, which is characterized by comprising the following steps: dissolving a compound of formula A in an organic solvent, adding a condensing agent TBTU and an alkali promoter DBU, stirring uniformly, heating the system to 40-60 DEG C, keeping the temperature to react for 23 hours, cooling to room temperature after the reaction is detected by TLC, and adding an ammonium chloride solution to quench the reaction, and performing extraction and separation to obtain the Lorlatinib. According to the invention, theTBTU is used as the condensing agent, DBU is used as the alkali promoter, and the TBTU and the DBU are combined for use, so compared with the prior art, the use amounts of the condensing agent and thealkali promoter used in the invention are obviously reduced, the reaction time is shorter, but the reaction yield is much higher than that in the prior art, and the method is very suitable for industrial production.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 1454846-35-5